华睿睿银、国中投资加持，估值25亿德适生物冲刺港交所IPO

Core Viewpoint - Deshi Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor, indicating a significant step towards public offering and potential growth in valuation [2]. Company Structure and Ownership - The founder, Song Ning, holds a direct stake of 30.04% and, through various investment platforms, controls a total of 52.06% voting rights, maintaining a dominant position as the controlling shareholder [2]. - The company was established in September 2016 with a registered capital of 1 million yuan, initially owned by Song Ning (90%) and his father (10%) [6]. - Over the years, Song Ning's direct shareholding has fluctuated, with a notable decrease to 47.95% after a capital increase in April 2019, but he later repurchased shares to increase his stake to 57.26% [6]. Investment and Valuation - Deshi Biotechnology has attracted multiple rounds of investment from various investors, with a post-investment valuation projected to reach 2.56 billion yuan by June 2025 [2]. - The company has undergone several capital increases, including a 15.56% stake acquisition by Hangzhou Zicheng in December 2016 and a 1.5 million yuan investment from Yuhang Industrial Fund in April 2019 [6][7]. Share Transfer and Control - The share transfer dynamics indicate that Song Ning has consistently retained control over the company, even as his direct ownership percentage has varied [4]. - Notably, the Yuhang Industrial Fund transferred a 5.24% stake back to Song Ning in April 2022 for 1.5 million yuan, further consolidating his control [7].